CRPC Clinical Trials in Beijing, Beijing Municipality
4 recruitingBeijing, Beijing Municipality, China
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846
Recruiting
Phase 1
A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
mCRPC
Jinming Zhang36 enrolled3 locationsNCT07096128